Primary Central Nervous System Lymphoma: A Literature Review, Diagnosis, Treatment, and Prognosis

Selmi Faikovna Ramazanova, A.V. Arakelyan, A.A. Semenova, O.Yu. Baranova, D.N. Tupitsyna, M.Yu. Kichigina, O.P. Trofimova, G.D. Petrova, A.S. Subbotin, V.O. Shpirko, U.G. Koshkina, N.O. Zemlyakov, K.R. Gadzhibekov, G.S. Tumyan,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-2-191-203

BACKGROUND. Primary lymphoma of the CNS (PLCNS) is one of the rare extranodal lymphoid tumors, which, in the vast majority of cases, is represented by diffuse large B-cell lymphoma (DLBCL). Tumor location, poor performance status with frequent neurological deficits as well as elderly age of the majority of patients restrict the opportunities for both diagnosis and treatment of this disease.

AIM. To study the clinical manifestations and chemotherapy options for patients with newly diagnosed PLCNS.

MATERIALS & METHODS. This study was based on the clinical data from 29 PLCNS patients treated at the Drug Chemotherapy and Hematology Department of the NN Blokhin National Medical Cancer Research Center from 2020 to 2025. The median age was 57 years (range 34–71 years), 35 % of patients were over 60 years of age, there were 16 (55 %) men. On presentation, more than a half of patients (n = 18; 62 %) had poor performance status (ECOG > 2). By immunohistochemical analysis, DLBCL was diagnosed in all patients: in 22 cases stereotactic biopsy was performed to verify the diagnosis, whereas in 7 cases open surgery was needed. An absolute majority of patients (n = 26; 90 %) received high-dose methotrexate (3–3.5 g/m2) as part of various combined regimens: R-MVT in 19 (66 %), R-MVР in 2 (7 %), R2-MV in 4 (14 %), and R-МAra-C in 1 (3 %) cases. Those 14 (48 %) patients who achieved antitumor effect after 2–4 cycles underwent consolidation in the form of external beam radiation therapy (n = 6; 21 %) or high-dose chemotherapy (n = 8; 28 %) with autologous hematopoietic stem cell transplantation (auto-HSCT). Maintenance therapy with temozolomide or lenalidomide was administered to 10 (35 %) patients.

RESULTS. With the median follow-up of 13 months, the 2-year progression-free survival (PFS) was 34.5 % (median 9 months), and the 2-year overall survival (OS) was 54.3 % (median 35 months). The most important prognostic factor was achievement of complete remission (CR): the median PFS in patients with CR was 17 months vs. 2 months in patients without it, the median OS was 35 months and 5 months, respectively. Consolidation therapy, regardless of the method used (radiation therapy or auto-HSCT), also considerably improved the rates of long-term survival: the 2-year PFS was 55.1 % vs. 9.7 % without consolidation, the 2-year OS was 79.5 % and 30.5 %, respectively.

CONCLUSION. PLCNS is characterized by a highly aggressive course. Administration of methotrexate-based regimens combined with alkylating or immunomodulatory agents followed by consolidation therapy is associated with improved rates of long-term survival. The results of first-line therapy present a key factor in determining the outcome of the disease, since the available treatment options for relapsed/refractory tumors of this kind are extremely limited and hardly effective.

  1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–48. doi: 10.1038/s41375-022-01620-2. DOI: https://doi.org/10.1038/s41375-022-01620-2
  2. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. doi: 10.1182/blood-2003-05-1545. DOI: https://doi.org/10.1182/blood-2003-05-1545
  3. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72. doi: 10.1200/JCO.2003.09.139. DOI: https://doi.org/10.1200/JCO.2003.09.139
  4. Bessell EM, Graus F, Lopez-Guillermo A, et al. Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;59(2):501–8. doi: 10.1016/j.ijrobp.2003.11.001. DOI: https://doi.org/10.1016/j.ijrobp.2003.11.001
  5. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5. doi: 10.1200/JCO.2006.08.2941. DOI: https://doi.org/10.1200/JCO.2006.08.2941
  6. Liu CJ, Lin SY, Yang CF, et al. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med. 2020;9(6):2134–45. doi: 10.1002/cam4.2872. DOI: https://doi.org/10.1002/cam4.2872
  7. Ferreri AJM, Illerhaus G, Doorduijn JK, et al. Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hemasphere. 2024;8(6):e89. doi: 10.1002/hem3.89. DOI: https://doi.org/10.1002/hem3.89
  8. Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94(10):e1027–e1039. doi: 10.1212/WNL.0000000000008900. DOI: https://doi.org/10.1212/WNL.0000000000008900
  9. Ostertag CB, Mennel HD, Kiessling M. Stereotactic biopsy of brain tumors. Surg Neurol. 1980;14(4):275–83.
  10. Au KLK, Latonas S, Shameli A, et al. Cerebrospinal Fluid Flow Cytometry: Utility in Central Nervous System Lymphoma Diagnosis. Can J Neurol Sci. 2020;47(3):382–8. doi: 10.1017/cjn.2020.22. DOI: https://doi.org/10.1017/cjn.2020.22
  11. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. doi: 10.1200/JCO.2012.45.2011. DOI: https://doi.org/10.1200/JCO.2012.45.2011
  12. Hernández-Verdin I, Morales-Martínez A, Hoang-Xuan K, Alentorn A. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies. Curr Opin Neurol. 2022;35(6):779–86. doi: 10.1097/WCO.0000000000001115. DOI: https://doi.org/10.1097/WCO.0000000000001115
  13. Montesinos-Rongen M, Godlewska E, Brunn A, et al. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011;122(6):791–2. doi: 10.1007/s00401-011-0891-2. DOI: https://doi.org/10.1007/s00401-011-0891-2
  14. Poulain S, Boyle EM, Tricot S, et al. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. Br J Haematol. 2015;170(2):285–7. doi: 10.1111/bjh.13293. DOI: https://doi.org/10.1111/bjh.13293
  15. Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016;131(6):865–75. doi: 10.1007/s00401-016-1536-2. DOI: https://doi.org/10.1007/s00401-016-1536-2
  16. Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–90. doi: 10.1111/nan.12259. DOI: https://doi.org/10.1111/nan.12259
  17. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017;7(9):1018–29. doi: 10.1158/2159-8290.CD-17-0613.
  18. Ferreri AJM, Calimeri T, Lopedote P, et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol. 2021;193(3):497–505. doi: 10.1111/bjh.17357. DOI: https://doi.org/10.1111/bjh.17357
  19. Navrkalova V, Mareckova A, Hricko S, et al. Reliable detection of CNS lymphoma-derived circulating tumor DNA in cerebrospinal fluid using multi-biomarker NGS profiling: insights from a real-world study. Biomark Res. 2025;13(1):71. doi: 10.1186/s40364-025-00777-z. DOI: https://doi.org/10.1186/s40364-025-00777-z
  20. Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018;109(1):225–30. doi: 10.1111/cas.13450. DOI: https://doi.org/10.1111/cas.13450
  21. Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, et al. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. Crit Rev Oncol Hematol. 2018;127:56–65. doi: 10.1016/j.critrevonc.2018.05.010. DOI: https://doi.org/10.1016/j.critrevonc.2018.05.010
  22. Rimelen V, Ahle G, Pencreach E, et al. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun. 2019;7(1):43. doi: 10.1186/s40478-019-0692-8. DOI: https://doi.org/10.1186/s40478-019-0692-8
  23. Watanabe J, Natsumeda M, Okada M, et al. High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas. JCO Precis Oncol. 2019;3:1–13. doi: 10.1200/PO.18.00308. DOI: https://doi.org/10.1200/PO.18.00308
  24. Gupta M, Burns EJ, Georgantas NZ, et al. A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood. 2021;138(5):382–6. doi: 10.1182/blood.2020010137. DOI: https://doi.org/10.1182/blood.2020010137
  25. Yamagishi Y, Sasaki N, Nakano Y, et al. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer Sci. 2021;112(11):4702–10. doi: 10.1111/cas.15133. DOI: https://doi.org/10.1111/cas.15133
  26. Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716–23. doi: 10.1182/blood-2005-03-0897. DOI: https://doi.org/10.1182/blood-2005-03-0897
  27. Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740–8. doi: 10.1182/blood-2013-01-476333. DOI: https://doi.org/10.1182/blood-2013-01-476333
  28. Montesinos-Rongen M, Schäfer E, Siebert R, Deckert M. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol. 2012;124(6):905–6. doi: 10.1007/s00401-012-1064-7. DOI: https://doi.org/10.1007/s00401-012-1064-7
  29. Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019;21(3):306–13. doi: 10.1093/neuonc/noy193. DOI: https://doi.org/10.1093/neuonc/noy193
  30. Braggio E, Van Wier S, Ojha J, et al. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res. 2015;21(17):3986–94. doi: 10.1158/1078-0432.CCR-14-2116. DOI: https://doi.org/10.1158/1078-0432.CCR-14-2116
  31. Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81. doi: 10.1182/blood-2015-10-673236. DOI: https://doi.org/10.1182/blood-2015-10-673236
  32. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. doi: 10.1182/blood-2014-10-604561.
  33. Canovi S, Campioli D. Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms: A systematic review. Diagn Cytopathol. 2016;44(10):841–56. doi: 10.1002/dc.23539. DOI: https://doi.org/10.1002/dc.23539
  34. Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;37(10):823–33. doi: 10.1200/JCO.18.00306. DOI: https://doi.org/10.1200/JCO.18.00306
  35. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20. doi: 10.1016/S0140-6736(09)61416-1. DOI: https://doi.org/10.1016/S0140-6736(09)61416-1
  36. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227. doi: 10.1016/S2352-3026(16)00036-3. DOI: https://doi.org/10.1016/S2352-3026(16)00036-3
  37. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Feb 26;125(9):1403–10. doi: 10.1182/blood-2014-10-604561. DOI: https://doi.org/10.1182/blood-2014-10-604561
  38. Звонков Е.Е., Королева Д.А., Габеева Н.Г. и др. Высокодозная химиотерапия первичной диффузной В-крупноклеточной лимфомы центральной нервной системы. Промежуточные результаты протокола CNS-2015. Гематология и трансфузиология. 2019;64(4):447–61. doi: 10.35754/0234-5730-2019-64-4-447-461. [Zvonkov E.E., Koroleva D.A., Gabeeva N.G., et al. High-dose chemotherapy for primary diffuse large B-cell lymphoma of the central nervous system. Interim results of the CNS-2015 protocol. Russian journal of hematology and transfusiology. 2019;64(4):447–61. doi: 10.35754/0234-5730-2019-64-4-447-461. (In Russ)] DOI: https://doi.org/10.35754/0234-5730-2019-64-4-447-461
  39. Yi JH, Kim SJ, Kim SA, et al. Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study. Cancer Res Treat. 2025;57(2):590–6. doi: 10.4143/crt.2024.531. DOI: https://doi.org/10.4143/crt.2024.531
  40. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017;7(9):1018–29. doi: 10.1158/2159-8290.CD-17-0613. DOI: https://doi.org/10.1158/2159-8290.CD-17-0613
  41. Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–45. doi: 10.1182/blood-2018-09-875732. DOI: https://doi.org/10.1182/blood-2018-09-875732
  42. Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol. 2019;30(4):621–8. doi: 10.1093/annonc/mdz032. DOI: https://doi.org/10.1093/annonc/mdz032
  43. Godfrey JK, Gao L, Shouse G, et al. Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma. Blood. 2024;144(4):457–61. doi: 10.1182/blood.2024024168. DOI: https://doi.org/10.1182/blood.2024024168
  44. Wang W, Chen M, Li J, et al. Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma. Leuk Lymphoma. 2025;66(8):1475–80. doi: 10.1080/10428194.2025.2484365. DOI: https://doi.org/10.1080/10428194.2025.2484365
  45. Tu S, Zhou X, Guo Z, et al. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Front Oncol. 2019;9:1350. doi: 10.3389/fonc.2019.01350. DOI: https://doi.org/10.3389/fonc.2019.01350
  46. Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022;139(5):792–6. doi: 10.1182/blood.2021012932. DOI: https://doi.org/10.1182/blood.2021012932
  47. Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–6. doi: 10.1182/blood.2019001694. DOI: https://doi.org/10.1182/blood.2019001694
  48. Liwei Lv, Yuchen Wu, Han Shi. Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis. Cancer Immunol Immunother. 2022;72(1):211–21. doi: 10.1007/s00262-022-03246-w. DOI: https://doi.org/10.1007/s00262-022-03246-w

Keywords:

primary central nervous system lymphoma, diagnosis, treatment

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Selmi Faikovna Ramazanova,  , NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522, e-mail: selya.ramazanova@bk.ru
2026-2

Downloads

Published

01.04.2026

Issue

Vol. 19 No. 2 (2026)
LYMPHOID TUMORS

How to Cite

Ramazanova S.F., Arakelyan A.V., Semenova A.A., et al. Primary Central Nervous System Lymphoma: A Literature Review, Diagnosis, Treatment, and Prognosis. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(2):191–203. doi:10.21320/2500-2139-2026-19-2-191-203.

Most read articles by the same author(s)

1 2 3 4 > >>